AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Original) Oxaliplatinum stable pharmaceutical preparation for parenteral administration, characterized in that the oxaliplatinum is contained in a solution in a solvent at a concentration of at least 7 mg/ml and in that said solvent comprises a sufficient quantity of a hydroxylated derivative selected among 1,2-propanediol, glycerol, maltitol, saccharose and inositol.
- 2. (Original) Pharmaceutical preparation according to claim 1, characterized in that the oxaliplatinum is contained in a solution in said solvent at a concentration of at least 9 mg/ml and in that 1 ml of said solvent comprises at least 100 mg of one or several of said hydroxylated derivatives.
- 3. (Currently Amended) Pharmaceutical preparation according to claim 2, characterized in that said solvent <u>further</u> comprises water.
- 4. (Original) Pharmaceutical preparation according to claim 3, characterized in that the oxaliplatinum is contained in a solution in said solvent at a concentration comprised between about 10 mg/ml and about 15 mg/ml.
- 5. (Previously Amended) Pharmaceutical preparation according to claim 1, characterized in that it is packed in an appropriate container for parenteral administration.
- 6. (Original) Pharmaceutical preparation according to claim 5, characterized in that said container is a multidoses flask.
- 7. (Original) Pharmaceutical preparation according to claim 5, characterized in that said container is a prefilled syringe.

IBRAHIM et al Appl. No. 10/049,379 September 17, 2004

- 8. (Original) Pharmaceutical preparation according to claim 5, characterized in that said container is a soft perfusion bag.
- 9. (Original) Pharmaceutical preparation according to claim 5, characterized in that said container is an ampoule.
- 10. (Previously Amended) Method for the preparation of a pharmaceutical preparation according to claim 1 comprising a step of mixing oxaliplatinum with a solvent comprising a sufficient quantity of at least one hydroxylated derivative selected among 1,2-propanediol, glycerol, maltitol, saccharose and inositol.
- 11. (Previously Presented) Method according to claim 10, characterized in that it comprises the following steps:
 - a) put in contact at a temperature less than 80°C a quantity of oxaliplatinum with a sufficient quantity of the said solvent to obtain an oxaliplatinum concentration of at least 7 mg/ml;
 - b) establish the mixture obtained at the step a) at a temperature comprised between 15-30°C;
 - c) submit the mixture obtained at the step b) to an aseptic filtration; and
 - d) the conservation in an adapted container for a parenteral administration of the mixture obtained at the step c) at a temperature comprised between 2-30°C.
- 12. (Cancelled).
- 13. (Cancelled).
- 14. (Cancelled)
- 15. (Previously Presented) A multidoses flask containing the pharmaceutical preparation according to claim 1.

IBRAHIM et al Appl. No. 10/049,379 September 17, 2004

- 16. (Previously Presented) A prefilled syringe containing the pharmaceutical preparation according to claim 1.
- 17. (Previously Presented) A soft perfusion bag containing the pharmaceutical preparation according to claim 1.